title: Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
abstract: Resistance to antiretroviral drugs is an increasingly prevalent challenge affecting both the adult and pediatric HIV-infected populations. Though data on the safety, pharmacokinetics, and efficacy of newer antiretroviral agents in children typically lags behind adult data, newer agents are becoming available for use in HIV-infected children who are failing to respond to or are experiencing toxicities with traditional antiretroviral regimens. Integrase strand transfer inhibitors are one such new class of antiretrovirals. Raltegravir has been US Food and Drug Administration (FDA) approved for use in patients over the age of 4 weeks. Elvitegravir is a second member of this class, and has the potential for use in children but does not yet have a Pediatric FDA indication. Dolutegravir, a second-generation integrase inhibitor, is approved for those older than 12 years. This review summarizes the use of integrase inhibitors in children and adolescents, and highlights the results of recent clinical trials.
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The University of New Mexico, MSC10 5590, 1 University of New Mexico, Albuquerque, NM, 87131-0001, USA, WDehority@salud.unm.edu.
authors.forename: Walter
authors.initials: W
authors.lastname: Dehority
authors.forename: Jacobo
authors.initials: J
authors.lastname: Abadi
authors.forename: Andrew
authors.initials: A
authors.lastname: Wiznia
authors.forename: Rolando M
authors.initials: RM
authors.lastname: Viani
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D017277:Drug Approval; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006575:Heterocyclic Compounds, 3-Ring / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D015363:Quinolones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068898:Raltegravir Potassium / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000099226:Dolutegravir
chemical_list: D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D015363:Quinolones; D000068898:Raltegravir Potassium; D000099226:Dolutegravir; C509700:elvitegravir